Primate liver as an alternative substrate in EmA testing: implications for celiac disease serology
Background Endomysial antibody (EmA) testing by immunofluorescence assay (IFA) on primate esophagus is widely used as reference approach in celiac disease (CD) serology in the United States (US). Practical constraints related to tissue availability and variability have motivated the evaluation of alternative substrates. Methods We compared analytical performance between the following substrates: primate esophagus (reference), primate liver, and a tTG-transfected cell-based assay (CBA) using 54 celiac disease-positive sera (EmA-positive, anti-tTG IgA-positive, and/or anti-dGP-IgG-positive) and 62 non-celiac disease controls (autoimmune liver disease, symptomatic controls, healthy) at screening dilution (1:10) and serial dilution up to 1:100,000. Agreement analyses included negative percent agreement (NPA), positivity in CD-positive samples, 95% Wilson confidence intervals, and discrepant result characterization. Results At screening dilution, NPA was 100% (62/62) for esophagus and 98.4% (61/62) for both liver and tTG-transfected cells. Among CD-positive samples at 1:10, positivity was 74.1% (40/54) on esophagus, 96.3% (52/54) on liver, and 100% (54/54) on tTG-transfected cells. Of the 14 esophagus-negative CD-positive samples, liver classified 12/14 as positive and the tTG -CBA classified 14/14 as positive. Titer-dependent positivity declined in parallel across substrates (1:100: 59.3–68.5%; 1:1000: 18.5–24.1%), with overlapping confidence intervals. Discrepant cases (esophagus-negative but liver-positive) were consistently positive on tTG-CBA. Conclusion Primate liver demonstrates higher screening-dilution positivity than primate esophagus, supporting its use as a scalable alternative substrate in EmA-IFA. The tTG-transfected CBA showed the highest positivity and may serve as a complementary confirmatory platform. Primate esophagus retained complete negative agreement in this cohort, whereas primate liver and the tTG-transfected CBA each showed one reactive control sample. Larger multicenter studies with histology-linked outcomes are warranted.
Authors
- Michael Schwalbe
- Danielle A. Cervasio
- Rama Chaar
- Marco Kai (ORCID: https://orcid.org/0000-0002-6131-2054)
- Tanja Seifert
- Maite Sabalza
Institutions
- Prometheus Biosciences (United States) (US)
- Euroimmun Medizinische Labordiagnostika (Germany) (DE)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-11-16
- DOI
- https://doi.org/10.3389/fimmu.2026.1939825
- Primary Topic
- Celiac Disease Research and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00